Pneumococcal Vaccine Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers Pneumococcal Vaccines Market Trends and It is Segmented by Vaccine Type (Conjugate Vaccine, Polysaccharide Vaccine), Product Type (Prevnar 13, Synflorix, and Pneumovax23), Distribution Channel (Distribution Partner Companies, Non-Governmental Organizations, and Government Authorities), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (in USD) for the Above Segments.

Pneumococcal Vaccine Market Size

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Pneumococcal Vaccines Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 8.80 Billion
Market Size (2029) USD 11.20 Billion
CAGR (2024 - 2029) 4.83 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Pneumococcal Vaccines Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Pneumococcal Vaccine Market Analysis

The Pneumococcal Vaccines Market size is estimated at USD 8.80 billion in 2024, and is expected to reach USD 11.20 billion by 2029, growing at a CAGR of 4.83% during the forecast period (2024-2029).

This pandemic had a dramatic effect throughout the world, especially in developing countries and on their country's healthcare systems, with significant impacts not only on the patients infected with COVID-19 but others as well, which resulted in disruption in research and development activities. The outbreak of COVID-19 showed a bit positive impact on the pneumococcal vaccine market. They can also be applied in the treatment of COVID-19. However, during the early lockdown, the immunization programs were halted, which later gain paced has impacted the market's growth. Additionally, the increased usage of the pneumococcal vaccine in COVID-19 patients has boosted the market's growth. For Instance, the Vaccine Journal article published in December 2021 concluded that Underlying medical conditions of patients of any age with S. pneumonia increase the risk of severe illness; COVID-19 was considered a primary risk factor for pneumococcal Pneumonia and invasive pneumococcal disease. It also suggested that pneumococcal vaccination during the COVID-19 pandemic was more critical than ever. Also, the studies showed positive results of pneumococcal vaccination in patients with COVID-19 and underlying medical conditions. Such studies boosted the market growth during the pandemic. In the coming years, the market is expected to witness significant growth owing to the increase in research activities and pipeline studies for the pneumococcal vaccine across the globe.

Factors such as the growing burden of Pneumonia cases, increasing government awareness programs regarding pneumonia immunization programs, and the introduction of novel pneumococcal vaccines are expected to bolster the market growth over the forecast period. For instance, in March 2022, the Ministry of Health and Family Welfare, as part of the National Health Mission's Reproductive, Maternal, Newborn, Child, Adolescent, and Adolescent Health and Nutrition (RMNCHA+N) program, developed the SAANS (Social Awareness and Actions to Neutralize Pneumonia Successfully) Initiative to reduce deaths from Childhood Pneumonia in both rural and urban areas which are expected to show significant growth over the forecast period.

Several market players are actively involved in developing novel vaccines and are in different phases of clinical trials. For Instance, in April 2022, Merck reported that its investigational 21-valent pneumococcal conjugate vaccine, V116, has received breakthrough therapy designation from the United States Food And Drug Administration (FDA) for the prevention of Invasive Pneumococcal Disease (IPD) and pneumococcal Pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. The positive results from such clinical trials may lead to the introduction of novel vaccines in the market and thus expected to propel the growth of the market. Moreover, in June 2021, PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) developed by Pfizer has been approved by the United States Food and Drug Administration (FDA) for the prevention of invasive illness and pneumonia caused by the 20 Streptococcus pneumonia (pneumococcus) serotypes in the vaccine in adults aged 18 and above. Furthermore, in June 2022, Researchers at Karolinska Institutet identified a new vaccine candidate against pneumococci, bacteria that can cause pneumonia, sepsis, and meningitis. The vaccine molecules comprise nano-sized membrane vesicles produced by the bacteria and provide protection in mice.

Hence, owing to the increase in awareness regarding pneumonia and the rise in product launches, the studied market is expected to witness significant growth over the forecast period. However, the high cost involved in producing vaccines and the long process duration is the major drawbacks to market growth.

Pneumococcal Vaccine Market Trends

Pneumococcal Conjugate Vaccine Segment is Anticipated to Witness a Growth in the Market Over the Forecast Period

The pneumococcal conjugate vaccine helps protect against bacteria that cause pneumococcal disease. Three pneumococcal conjugate vaccines exist (PCV13, PCV15, and PCV20). Different vaccines are recommended for people based on age and medical status. PCV13 is for infants and children. PCV15 or PCV20 vaccines are for adults 19 through 64 years old. The studied segment is expected to witness significant growth in the studied market owing to the increasing developments and initiatives, rise in strategic activities by the key players, and surge in investments for the pneumococcal conjugate vaccine development, which are expected to boost the segment growth.

For instance, in May 2021, Pfizer Inc. publicized that its first enrolled subjects had received their immunizations as part of a new study in adults ages 65 or older exploring the coadministration of the company's 20-valent pneumococcal conjugate vaccine (20vPnC) candidates following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine, currently authorized by FDA under an Emergency Use Authorization. The trial's primary objective was to describe safety when both vaccines are co-administered, with follow-up six months after vaccination. The secondary objectives are to describe the immune responses produced by each vaccine. Also, in July 2021, Merck received FDA approval for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in adults 18 years and older caused by 15 serotypes. VAXNEUVANCE was approved based on data from seven randomized, double-masked clinical studies assessing safety, tolerability, and immunogenicity in adults.

Similarly, many vaccine programs are being conducted across the globe, which is positively impacting market growth. For instance, in November 2021, the Pneumococcal Conjugate Vaccine (PCV) program was launched under the universal immunization program in Bengaluru, India. Chief Minister Basavaraj Bommai launched the program in the State on October 22 at KIMS, Hubballi. Moreover, in May 2022, the Union health minister of India launched the nationwide expansion of Pneumococcal Conjugate Vaccine (PCV) under the Universal Immunisation Programme (UIP) as part of the "Azadi ka Amrit Mahotsav" initiative marking 75 years of India's independence. Therefore, the increasing initiatives by the governments and the growing launches and trials have been expected to boost the segment growth in the forecast period.

Therefore, with an increase in strategic activities by the key players and increased research activities and government initiatives, the studied segment is expected to witness significant growth over the forecast period.

Pneumococcal Vaccines Market: Estimated Research Funding for Pneumonia (in USD Million), United States, 2021-2023

North America Anticipated to Hold a Significant Market Share Over the Forecast Period

North America is expected to hold significant market growth in the overall market throughout the forecast period owing to factors such as the presence of key players and established healthcare infrastructure, which are the key factors accountable for its large share in the market. Also, an increase in investment in the development of pneumococcal vaccines and a rise in pneumonia cases in the studied region is expected to contribute to the market growth.

According to the National Foundation for Infectious Diseases, updated in March 2022, pneumococcal pneumonia hospitalizes around 150,000 individuals in the United States each year. The region's high prevalence of pneumococcal infection is expected to drive market growth. Also, according to the January 2023 update by the CDC, the percentage of adults aged 18 and over who had ever received a pneumococcal vaccination was 24.0% in 2021 in the United States. Hence, an increase in pneumonia cases is expected to increase the demand for pneumococcal vaccines in the studied region, bolstering market growth over the forecast period.

Furthermore, the presence of key market players and developed healthcare infrastructure are the main reasons for the market's large share. In July 2021, Merck's VAXNEUVANCE(Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) was approved by FDA for active immunization to prevent invasive diseases caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in adults aged 18 years and older. Similarly, Health Canada authorized two new pneumococcal vaccines for adults 18 and older, Prevnar 20 (PNEU-C-20) on May 9, 2022, and Vaxneuvance (PNEU-C-15) on November 16, 2021. Vaxneuvance was also authorized for infants and children aged 6 months to 17 on July 8, 2022. Thus, an increase in approvals and product launches of pneumococcal vaccines in the studied region is expected to augment the market growth over the forecast period.

Thus, owing to the increase in pneumonia cases and increasing strategic activities coupled with government approvals, the market in the region is projected to grow over the forecast period.

Pneumococcal Vaccines Market - Growth Rate By Region

Pneumococcal Vaccine Industry Overview

The pneumococcal vaccine market is highly consolidated and consists of a few players. Some companies currently dominating the market are GSK plc, Pfizer Inc., CSL Ltd., Merck KGaA, Serum Institute of India Pvt. Ltd., and Sanofi.

Pneumococcal Vaccine Market Leaders

  1. Pfizer Inc.

  2. CSL Ltd.

  3. Serum Institute of India Pvt. Ltd.

  4. GSK plc

  5. Merck KGaA

*Disclaimer: Major Players sorted in no particular order

Pneumococcal Vaccines Market Concentration
Need More Details on Market Players and Competitors?
Download PDF

Pneumococcal Vaccine Market News

  • January 2023: U.S. Food and Drug Administration (FDA) accepted for priority review the supplemental biologics license application for Pfizer's 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine in infants and children 6 weeks through 17 years of age, and for the prevention of otitis media caused by seven of the 20 Streptococcus pneumoniae serotypes contained in the vaccine.
  • May 2022: GSK committed USD 3.3 billion to acquire Affinivax, a clinical-stage vaccine developer with a Phase III-ready vaccine candidate that addresses more bacterial strains than any pneumococcal vaccine currently available.

Pneumococcal Vaccine Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Government Awareness Programs Regarding Pneumonia Immunization

      2. 4.2.2 Rising Prevalence Of Pneumonia

      3. 4.2.3 Introduction of Novel Pneumococcal Vaccines

    3. 4.3 Market Restraints

      1. 4.3.1 Long Duration for the Production

      2. 4.3.2 High Cost of Production

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Buyers/Consumers

      2. 4.4.2 Bargaining Power of Suppliers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 5.1 By Vaccine Type

      1. 5.1.1 Pneumococcal conjugate vaccine

      2. 5.1.2 Pneumococcal polysaccharide vaccine

    2. 5.2 By Product Type

      1. 5.2.1 Prevnar 13

      2. 5.2.2 Synflorix

      3. 5.2.3 Pneumovax23

    3. 5.3 By Distribution Channel

      1. 5.3.1 Distribution partner companies

      2. 5.3.2 Non-governmental Organizations

      3. 5.3.3 Government Authorities

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 GSK plc

      2. 6.1.2 Pfizer Inc.

      3. 6.1.3 Merck KGaA

      4. 6.1.4 Serum Institute of India Pvt. Ltd.

      5. 6.1.5 CSL Ltd.

      6. 6.1.6 Sanofi S.A

      7. 6.1.7 Walvax Biotechnology Co., Ltd

      8. 6.1.8 Beijing Minhai Biotechnology Co.,Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Pneumococcal Vaccine Industry Segmentation

As per the scope of the report, Pneumonia is a type of acute respiratory illness that affects the lungs, in which the alveoli are filled with pus and fluid, making breathing painful and limiting oxygen intake. The Pneumococcal Vaccines Market is Segmented by Vaccine Type (Conjugate vaccine, Polysaccharide vaccine), Product Type (Prevnar 13, Synflorix, and Pneumovax23), Distribution Channel (Distribution partner companies, Non-governmental Organizations, and Government Authorities), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.

By Vaccine Type
Pneumococcal conjugate vaccine
Pneumococcal polysaccharide vaccine
By Product Type
Prevnar 13
Synflorix
Pneumovax23
By Distribution Channel
Distribution partner companies
Non-governmental Organizations
Government Authorities
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Pneumococcal Vaccine Market Research FAQs

The Pneumococcal Vaccines Market size is expected to reach USD 8.80 billion in 2024 and grow at a CAGR of 4.83% to reach USD 11.20 billion by 2029.

In 2024, the Pneumococcal Vaccines Market size is expected to reach USD 8.80 billion.

Pfizer Inc., CSL Ltd., Serum Institute of India Pvt. Ltd., GSK plc and Merck KGaA are the major companies operating in the Pneumococcal Vaccines Market.

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Pneumococcal Vaccines Market.

In 2023, the Pneumococcal Vaccines Market size was estimated at USD 8.37 billion. The report covers the Pneumococcal Vaccines Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Pneumococcal Vaccines Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

PCV Industry Report

Statistics for the 2024 PCV market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. PCV analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Pneumococcal Vaccine Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)